These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 36640794

  • 1. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E, GETAID and the SPARE-Biocycle research group.
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baía C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S, BERGAMOT Study Group.
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG.
    Cochrane Database Syst Rev; 2014 Aug 06; 2014(8):CD003459. PubMed ID: 25099640
    [Abstract] [Full Text] [Related]

  • 7. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T, UK Inflammatory Bowel Disease Pharmacogenetics Study Group.
    Lancet Gastroenterol Hepatol; 2019 May 06; 4(5):341-353. PubMed ID: 30824404
    [Abstract] [Full Text] [Related]

  • 8. Infliximab for maintenance of medically-induced remission in Crohn's disease.
    Gordon M, Sinopoulou V, Akobeng AK, Sarian A, Moran GW.
    Cochrane Database Syst Rev; 2024 Feb 19; 2(2):CD012609. PubMed ID: 38372447
    [Abstract] [Full Text] [Related]

  • 9. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N, Townsend CM, Parker CE, MacDonald JK.
    Cochrane Database Syst Rev; 2016 Oct 26; 10(10):CD000545. PubMed ID: 27783843
    [Abstract] [Full Text] [Related]

  • 10. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N, Tsoulis DJ, MacDonald JK.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD000545. PubMed ID: 23633304
    [Abstract] [Full Text] [Related]

  • 11. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
    Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK.
    Cochrane Database Syst Rev; 2015 Oct 30; 2015(10):CD000067. PubMed ID: 26517527
    [Abstract] [Full Text] [Related]

  • 12. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G.
    Lancet; 2017 Dec 23; 390(10114):2779-2789. PubMed ID: 29096949
    [Abstract] [Full Text] [Related]

  • 13. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Probert CS, Raine T, Saich R, Seward A, Sharpstone D, Smith MA, Subramanian S, Upponi SS, Wiles A, Williams HRT, van den Brink GR, Vermeire S, Jairath V, D'Haens GR, McKinney EF, Lyons PA, Lindsay JO, Kennedy NA, Smith KGC, Parkes M, PROFILE Study Group.
    Lancet Gastroenterol Hepatol; 2024 May 23; 9(5):415-427. PubMed ID: 38402895
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
    Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, Roberts C, Bishara M, Nice R, Lees CW, Sebastian S, Irving PM, Russell RK, McDonald TJ, Goodhand JR, Ahmad T, Kennedy NA, PANTS Consortium.
    Lancet Gastroenterol Hepatol; 2024 Jun 23; 9(6):521-538. PubMed ID: 38640937
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C.
    Lancet Gastroenterol Hepatol; 2021 Dec 23; 6(12):1002-1014. PubMed ID: 34688373
    [Abstract] [Full Text] [Related]

  • 16. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
    Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T, HAYABUSA Study Group.
    Lancet Gastroenterol Hepatol; 2021 Jun 23; 6(6):429-437. PubMed ID: 33887262
    [Abstract] [Full Text] [Related]

  • 17. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
    Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA, LIR!C study group.
    Lancet Gastroenterol Hepatol; 2017 Nov 23; 2(11):785-792. PubMed ID: 28838644
    [Abstract] [Full Text] [Related]

  • 18. Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
    Syal G, Melmed GY, Almario CV, Spiegel BMR.
    Dig Dis Sci; 2023 Feb 23; 68(2):404-413. PubMed ID: 36512266
    [Abstract] [Full Text] [Related]

  • 19. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F, LADI study group and the Dutch Initiative on Crohn and Colitis.
    Lancet Gastroenterol Hepatol; 2023 Apr 23; 8(4):343-355. PubMed ID: 36736339
    [Abstract] [Full Text] [Related]

  • 20. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
    Pierre N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, Fléron M, Trzpiot L, Eppe G, De Pauw E, Laharie D, Satsangi J, Bossuyt P, Vuitton L, Vieujean S, Colombel JF, Meuwis MA, Louis E, GETAID and the SPARE-Biocycle research group.
    Gut; 2024 Nov 11; 73(12):1965-1973. PubMed ID: 39134391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.